The drugmaker said it would launch late-stage trials of the drug after participants lost as much as 20% of their body weight.
Shares of Eli Lilly rose nearly 4% in premarket trading on Thursday after the pharmaceutical company reported third-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback